Aerovate Therapeutics, Inc. (AVTE)
- Previous Close
1.9800 - Open
1.9700 - Bid 1.9000 x 400
- Ask 1.9300 x 400
- Day's Range
1.9000 - 1.9899 - 52 Week Range
1.2500 - 32.4150 - Volume
468,826 - Avg. Volume
532,274 - Market Cap (intraday)
54.849M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1300 - Earnings Date Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.33
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
aerovatetx.comRecent News: AVTE
View MorePerformance Overview: AVTE
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVTE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVTE
View MoreValuation Measures
Market Cap
54.85M
Enterprise Value
-48.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.03%
Return on Equity (ttm)
-74.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-87.94M
Diluted EPS (ttm)
-3.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
104.2M
Total Debt/Equity (mrq)
0.72%
Levered Free Cash Flow (ttm)
-44.86M